The cautionary tale of side effects of chronic Notch1 inhibition

Journal of Clinical Investigation

Volumn 121, Issue 2, 2011, Pages 508-509

  Ryeom, Sandra W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DELTA LIKE 4 ANTIBODY; GAMMA SECRETASE INHIBITOR; NOTCH1 ANTIBODY; NOTCH1 RECEPTOR; NOTCH2 ANTIBODY; NOTCH2 RECEPTOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; CANCER GRAFT; CANCER INCIDENCE; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GOBLET CELL; HUMAN; IN VITRO STUDY; LIVER TUMOR; NONHUMAN; NOTE; ONCOGENE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CANCER; VASCULAR TUMOR;

ANIMALS; HUMANS; MEMBRANE PROTEINS; MICE; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; VASCULAR NEOPLASMS;

EID: 79551553121     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45976     Document Type: Note

References (12)

1. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol. 2008;3:587-613.
2. Hanlon L, et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 2010;70(11):4280- 4286.
3. Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of Notch ligands and receptors in non-small cell lung cancer: co-expression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer. 2010;116(24):5676-5685.
4. Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 2010;80(5):690-701.
5. Ridgway J, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444(7122):1083-1087.
6. Shih IeM, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67(5):1879-1882. (Pubitemid 46424200)
7. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3(10):756-767.
8. van Es JH, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959-963.
9. Wu Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291):1052-1057.
10. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol. 2004;5(3):247-253.
11. Yan M, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010;463(7282):E6-E7.
12. Liu Z, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest. 2011;121(2):800-808.